September 2017

New Product - Lonsurf

Lonsurf (trifluridine/ tipiracil (hydrochloride)) is comprised of an antineoplastic thymidine based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride, at a molar ratio 1:0.5. Trifluridine/ tipiracil hydrochloride demonstrated antitumor activity against both 5-fluorouracil (5-FU) sensitive and resistant colorectal cancer cell lines in nonclinical studies. Lonsurf is indicated for the treatment of adults with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for fluoropyrimidine, oxaliplatin and irinotecan based chemotherapies, anti-VEGF agents, and anti-EGFR agents. Lonsurf 15/6.14 (trifluridine 15 mg and tipiracil (hydrochloride) 6.14 mg)) and Lonsurf 20/8.19 (trifluridine 20 mg and tipiracil (hydrochloride) 8.19 mg) tablets are available in a pack of 20.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au